Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
ViroGates Announces its third clinical routine customer | ||
By: Nasdaq / GlobeNewswire - 25 Apr 2019 | Back to overview list |
|
Company announcement no. 5-2019 Birkerød, 25 April 2019 ViroGates A/S (Nasdaq First North Denmark: VIRO), who delivers blood test systems, primarily for acute care departments in hospitals, today announces that Amager Hospital, Denmark has entered an agreement with ViroGates as paying customer for the use of suPARnostic® TurbiLatex in clinical routine practice for the triage and severity assessment of acute clinical patients. The hospital is run by the Capital Region and treats approximately 50,000 patients annually of which approximately 16,000 are admitted for hospitalisation. The hospital is operating its own acute clinical department, while management of the hospital is jointly operated with Hvidovre Hospital. Professor, Dm.Sc, MD, Ove Andersen comments: “Over the last years, suPAR has shown to be a strong marker of risk in acute medical patients independent of the clinical signs used to triage patients. The addition of suPAR improves risk prediction of both low- and high-risk acute medical patients and suPAR can therefore corroborate the decision of admission or discharge. We are pleased that Amager Hospital will now have access to the knowledge provided by suPAR. For further information contact: ViroGates A/S Certified Advisor About ViroGates
Attachment |
||
|
||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |